AI + EXCLUSIVE DATA
AI analyzes funding data you can't access anywhere else
Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.
10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + real-time funding intelligence
✓Never see duplicates in your feed
INDUSTRY FIRST
Biofrontera announced it raised $7.11 Million in an initial filing from an offering of $7.11 Million
Aug 11, 2022•about 3 years ago
Amount Raised
$7.11 Million
WoburnHealth CareCompany Information
Location
Woburn, Massachusetts, United States
About
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne.
Company News
(10 articles)Mon, 04 Aug 2025 07:00:00 GMT
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 - GlobeNewswire
Wed, 11 Jun 2025 07:00:00 GMT
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG - GlobeNewswire
Mon, 30 Jun 2025 07:00:00 GMT
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - Yahoo Finance
Thu, 15 May 2025 07:00:00 GMT
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewswire
Tue, 03 Jun 2025 07:00:00 GMT
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - GlobeNewswire
Wed, 08 Jan 2025 08:00:00 GMT
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire
Thu, 01 May 2025 07:00:00 GMT
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire
Mon, 07 Oct 2024 07:00:00 GMT
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire
Mon, 11 Aug 2025 20:26:42 GMT
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer - GlobeNewswire
Wed, 13 Aug 2025 21:21:30 GMT
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
FundzWatch™ Score
84
Medium Activity
Related People
Sign in to view contact details
Sign in to view contact details